Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Aciphex Articles

Stock Commentary Tokyo

28 September 2000

MSDW explores US prescription sales in major therapeutic areas

6 July 2000

Stock Commentary Tokyo

6 April 2000

Stock Commentary Tokyo

3 April 2000

Japanese reaction to US vitamin lawsuits

15 September 1999

Eisai and Janssen's Aciphex cleared in USA

20 August 1999

Japanese drugmakers setting conservative targets for fiscal 2000

7 June 1999

Stock Commentary Tokyo

29 April 1999

Strong 1st quarters from US drug majors still disappoint some analysts

21 April 1999

Stock Commentary Tokyo

18 March 1999

Eisai's Pariet Gains Approval In Rest Of EU

15 October 1998

Stock Commentary Tokyo

23 April 1998

Eisai Files NDA For Aciphex

8 April 1998

Eisai And Janssen's PPI Deal

21 April 1997

Showing 101-114 of 114 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS